Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral loads in patients with moderate to severe COVID-19

What the survey did:
This randomized clinical trial compares the effects of three doses of bamlanivimab monotherapy (700 vs 2,800 vs 7,000 mg) vs. a combination of bamlanivimab and etesevimab vs placebo modified in day 11 of acute coronavirus viral syndrome 2 in patients with COVID -19 moderately mild.

Authors:
The corresponding author is Daniel M. Skovronsky, MD, Ph.D., of Eli Lilly and Company in Indianapolis.

To get to the embargo review:
Visit our For The Media website at this link
https: //media.jamanet work.com /

(doi: 10.1001 / jama.2021.0202)

Editor’s note: The articles cover conflicts of interest and funding / support disclosures. Please see the article for more information, including other authors, author contributions and links, conflicts of interest and financial publications, and funding and support.

###

Media Advisor:
The full article is linked to this news release.

Submit this link to give your readers free access to the full-text article
This link will be live during the embargo
https: //jamanet work.com /magazines /jama /fullarticle /10.1001 /jama.2021.0202? AoiAccessKey =3fec263c-09fb-401a-b5b9-3691cf340d8b & utm_source =For_The_Media & utm_medium =transmission & utm_campaign =ftm_links & utm_content =tfl & utm_term =012121

Disclaimer: AAAS and EurekAlert! they are not responsible for the accuracy of press releases posted to EurekAlert! by sending institutions or for using any information through the EurekAlert system.

.Source